27 September 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Result of Annual General Meeting
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at its Annual General Meeting held yesterday all resolutions proposed to the meeting were duly passed.
Votes received in relation to each resolution were as follows:
| Resolution | For |
% |
Discretionary |
% | Against |
% |
| 01 | 41,070,268 | 100.00 | Nil | 0.00 | Nil | 0.000 |
| 02 | 36,456,852 | 88.768 | Nil | 0.00 | 4,613,165 | 11.232 |
| 03 | 40,961,390 | 99.735 | Nil | 0.00 | 108,878 | 0.265 |
| 04 | 34,395,129 | 84.081 | Nil | 0.00 | 6,511,866* | 15.919 |
| 05 | 41,070,404 | 99.999 | Nil | 0.00 | 541 | 0.001 |
| 06 | 40,976,766 | 99.771 | Nil | 0.00 | 94,179 | 0.229 |
| 07 | 40,945,821 | 99.709 | 784 | 0.002 | 118,663 | 0.289 |
| 08 | 40,957,821 | 99.726 | 784 | 0.002 | 111,663 | 0.272 |
| 09 | 41,046,763 | 99.941 | 7,500 | 0.018 | 16,682 | 0.041 |
* Note: The Board has been informed that a shareholder holding a block of 1,902,729 votes incorrectly lodged a proxy in respect of these shares against resolution 4. This shareholder acknowledged that the intent had been to vote these shares in favour of resolution 4.
-Ends-
For further information please contact:
| |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
